Efficacy and Safety of Faster-acting Insulin Aspart Compared to NovoRapid Both in Combination With Insulin Degludec in Adults With Type 1 Diabetes
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 11 Aug 2017
At a glance
- Drugs Insulin aspart (Primary) ; Insulin degludec (Primary)
- Indications Type 1 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms onset8
- Sponsors Novo Nordisk
- 10 Jun 2017 Biomarkers information updated
- 25 Nov 2016 Status changed from recruiting to active, no longer recruiting.
- 11 May 2016 Status changed from not yet recruiting to recruiting.